BR0312921A - Composição compreendendo inibidor de reductase hmg-coa - Google Patents

Composição compreendendo inibidor de reductase hmg-coa

Info

Publication number
BR0312921A
BR0312921A BR0312921-7A BR0312921A BR0312921A BR 0312921 A BR0312921 A BR 0312921A BR 0312921 A BR0312921 A BR 0312921A BR 0312921 A BR0312921 A BR 0312921A
Authority
BR
Brazil
Prior art keywords
hmg
composition
coa reductase
reductase inhibitor
phase
Prior art date
Application number
BR0312921-7A
Other languages
English (en)
Inventor
Andreas Meyer
Joerg Ogorka
Sabine Desset-Br Thes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0312921A publication Critical patent/BR0312921A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO COMPREENDENDO INIBIDOR DE REDUCTASE HMG-COA". A presente invenção refere-se a composições farmacêuticas para liberação prolongada compreendendo, como ingrediente ativo, um inibidor de HMG-CoA reductase ou um sal farmaceuticamente do mesmo, referida composição compreendendo uma fase interna (interna) e uma fase externa (externa) em que pelo menos a fase externa compreende pelo menos um formador de matriz.
BR0312921-7A 2002-07-25 2003-07-24 Composição compreendendo inibidor de reductase hmg-coa BR0312921A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0217306.0A GB0217306D0 (en) 2002-07-25 2002-07-25 Compositions comprising organic compounds
PCT/EP2003/008179 WO2004010980A1 (en) 2002-07-25 2003-07-24 Compositions comprising hmg-coa reductase inhibitor

Publications (1)

Publication Number Publication Date
BR0312921A true BR0312921A (pt) 2005-06-14

Family

ID=9941130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312921-7A BR0312921A (pt) 2002-07-25 2003-07-24 Composição compreendendo inibidor de reductase hmg-coa

Country Status (9)

Country Link
US (1) US20050239884A1 (pt)
EP (1) EP1536775A1 (pt)
JP (1) JP2005538097A (pt)
CN (1) CN100536846C (pt)
AU (1) AU2003250172A1 (pt)
BR (1) BR0312921A (pt)
CA (1) CA2493761A1 (pt)
GB (1) GB0217306D0 (pt)
WO (1) WO2004010980A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
JP4987261B2 (ja) * 2005-07-13 2012-07-25 株式会社 メドレックス ゲル状経口製剤
AU2006309826B2 (en) * 2005-10-31 2012-01-19 Kowa Co., Ltd. Pharmaceutical preparation having excellent photostability
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
WO2009116061A2 (en) * 2008-01-10 2009-09-24 Alkem Laboratories Ltd. Stable oral pharmaceutical composition comprising atorvastatin
US20110003837A1 (en) * 2008-01-30 2011-01-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2012002464A1 (ja) 2010-06-30 2012-01-05 持田製薬株式会社 ω３脂肪酸の配合製剤
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
JP5988963B2 (ja) * 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
US9433638B1 (en) 2013-10-02 2016-09-06 University Of Kentucky Research Foundation Polymeric prodrug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
EP1324972A4 (en) * 2000-09-06 2004-06-30 Merck & Co Inc OPEN-CHAIN DIHYDROXY ACID SALT BY SIMVASTATIN
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof

Also Published As

Publication number Publication date
US20050239884A1 (en) 2005-10-27
EP1536775A1 (en) 2005-06-08
JP2005538097A (ja) 2005-12-15
AU2003250172A1 (en) 2004-02-16
CN1684669A (zh) 2005-10-19
CN100536846C (zh) 2009-09-09
GB0217306D0 (en) 2002-09-04
WO2004010980A1 (en) 2004-02-05
CA2493761A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
BR0312921A (pt) Composição compreendendo inibidor de reductase hmg-coa
BR0308613A (pt) Combinação de compostos orgânicos
BR0113661A (pt) Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2
BR0309528A (pt) Comprimido com alta carga de droga
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
BRPI0515594A (pt) inibidores da interação entre mdm2 e p53
CR10032A (es) Preparación sólida
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0510059A (pt) inibidores da transcriptase reversa não-nucleosìdica
BR0315454A (pt) Composições pesticidas
AR054581A1 (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
BR0210028A (pt) Agentes antibacterianos
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
DE602004020649D1 (de) Hdl-verstärkende kombinationstherapie-komplexe
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
WO2007005941A3 (en) Liver targeted conjugates
HK1110787A1 (en) Pharmaceutical composition comprising glutathione compounds and betalain for the prevention and treatment of cancer
BRPI0407181A (pt) Formulação farmacêutica
BR0107564A (pt) Composição de gliburida
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
BRPI0414822A (pt) método de inibir a produção de lipoproteìna remanescente

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.